{
    "eid": "2-s2.0-85074305335",
    "title": "Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: Long-term results of the PRIMA study",
    "cover-date": "2019-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [],
    "authors": [
        "Emmanuel Bachy",
        "John F. Seymour",
        "Pierre Feugier",
        "Fritz Offner",
        "Armando L\u00f3pez-Guillermo",
        "David Belada",
        "Luc Xerri",
        "John V. Catalano",
        "Pauline Brice",
        "Fran\u00e7ois Lemonnier",
        "Alejandro Martin",
        "Olivier Casasnovas",
        "Lars M. Pedersen",
        "V\u00e9ronique Dorvaux",
        "David Simpson",
        "Sirpa Leppa",
        "Jean Gabarre",
        "Maria G. Da Silva",
        "Sylvie Glaisner",
        "Loic Ysebaert",
        "Anne Vekhoff",
        "Tanin Intragumtornchai",
        "Steven Le Gouill",
        "Andrew Lister",
        "Jane A. Estell",
        "Gustavo Milone",
        "Anne Sonet",
        "Jonathan Farhi",
        "Harald Zeuner",
        "Herv\u00e9 Tilly",
        "Gilles Salles"
    ],
    "citedby-count": 131,
    "ref-count": 35,
    "ref-list": [
        "Follicular lymphoma: 2018 update on diagnosis and management",
        "The 2016 revision of the World Health Organization classification of lymphoid neoplasms",
        "The non-Hodgkin's lymphoma classification project",
        "CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma",
        "Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma",
        "Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study",
        "Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German study group hematology and oncology study",
        "Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group",
        "Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial",
        "Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)",
        "Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study",
        "Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule",
        "Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-A randomized phase II trial of the Minnie Pearl Cancer Research Network",
        "Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: A prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation",
        "Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study",
        "Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98",
        "Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial",
        "Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy",
        "Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",
        "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas",
        "New treatment options have changed the survival of patients with follicular lymphoma",
        "Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center",
        "Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma",
        "Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study",
        "Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: An individual patient-level analysis of multiple randomized trials",
        "Validation of surrogate endpoints in advanced solid tumors: Systematic review of statistical methods, results, and implications for policy makers",
        "Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: An individual patient-level analysis of multiple randomized trials (SEAL)",
        "Detecting an overall survival benefit that is derived from progression-free survival",
        "Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study",
        "Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy",
        "Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study",
        "Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: Benefit of obinutuzumab in reducing the rate of early progression",
        "Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial",
        "Rituximab maintenance for the treatment of patients with follicular lymphoma: An updated systematic review and meta-analysis of randomized trials",
        "Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project"
    ],
    "affiliation": [
        {
            "affiliation-city": "Marseille",
            "@id": "60102127",
            "affilname": "Aix Marseille Universit\u00e9",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60102127",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Ghent",
            "@id": "60033316",
            "affilname": "Universiteit Gent",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033316",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Buenos Aires",
            "@id": "60030914",
            "affilname": "Fundacion para Combatir La Leucemia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60030914",
            "affiliation-country": "Argentina"
        },
        {
            "affiliation-city": "Paris",
            "@id": "60030640",
            "affilname": "Institut Curie",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60030640",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Barcelona",
            "@id": "60030315",
            "affilname": "Hospital Clinic Barcelona",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60030315",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Salamanca",
            "@id": "60028352",
            "affilname": "Hospital Cl\u00ednico Universitario de Salamanca",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028352",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Dijon",
            "@id": "60028234",
            "affilname": "H\u00f4pital Fran\u00e7ois Mitterrand",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028234",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nantes",
            "@id": "60028048",
            "affilname": "CHU de Nantes",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028048",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60026553",
            "affilname": "University of Melbourne",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026553",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Thionville",
            "@id": "60025996",
            "affilname": "Centre Hospitalier R\u00e9gional Metz-Thionville",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025996",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Sydney",
            "@id": "60025709",
            "affilname": "The University of Sydney",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025709",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Creteil",
            "@id": "60023970",
            "affilname": "H\u00f4pital Henri Mondor",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023970",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Lisbon",
            "@id": "60023634",
            "affilname": "Instituto Portugues de Oncologia de Francisco Gentil Lisboa",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023634",
            "affiliation-country": "Portugal"
        },
        {
            "affiliation-city": "Rouen",
            "@id": "60023228",
            "affilname": "Centre Henri Becquerel",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023228",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "London",
            "@id": "60022109",
            "affilname": "Queen Mary University of London",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022109",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Paris",
            "@id": "60021567",
            "affilname": "AP-HP Assistance Publique - Hopitaux de Paris",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021567",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Frankston",
            "@id": "60021498",
            "affilname": "Frankston Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021498",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Auckland",
            "@id": "60021290",
            "affilname": "North Shore Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021290",
            "affiliation-country": "New Zealand"
        },
        {
            "affiliation-city": "Nancy",
            "@id": "60020606",
            "affilname": "CHU de Nancy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020606",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Helsinki",
            "@id": "60016987",
            "affilname": "Helsinki University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016987",
            "affiliation-country": "Finland"
        },
        {
            "affiliation-city": "Prague",
            "@id": "60016605",
            "affilname": "Charles University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016605",
            "affiliation-country": "Czech Republic"
        },
        {
            "affiliation-city": "Paris",
            "@id": "60015622",
            "affilname": "H\u00f4pital Universitaire Piti\u00e9 Salp\u00eatri\u00e8re",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015622",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Hellerup",
            "@id": "60014959",
            "affilname": "Copenhagen University Hospital \u2013 Herlev and Gentofte",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60014959",
            "affiliation-country": "Denmark"
        },
        {
            "affiliation-city": "Lyon",
            "@id": "60012357",
            "affilname": "CHU de Lyon",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012357",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Angers",
            "@id": "60009445",
            "affilname": "CHU Angers",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009445",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Basel",
            "@id": "60008201",
            "affilname": "F. Hoffmann-La Roche AG",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008201",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Paris",
            "@id": "60002900",
            "affilname": "H\u00f4pital Saint-Louis",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002900",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Lyon",
            "@id": "60001780",
            "affilname": "Centre Hospitalier Lyon-Sud",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60001780",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Yvoir",
            "@id": "119634231",
            "affilname": "UCL",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/119634231",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Toulouse",
            "@id": "116505678",
            "affilname": "Institut Universitaire du Cancer de Toulouse-Oncopole",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/116505678",
            "affiliation-country": "France"
        }
    ],
    "funding": [
        "Janis Noonan of Gardiner-Caldwell Communications",
        "Lymphoma Study Association",
        "F. Hoffmann-La Roche"
    ]
}